| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Licoisoflavone B targets multiple enzymes and pathways. It inhibits lipid peroxidation, a process involved in oxidative stress. It inhibits the human cytochrome P450 enzymes CYP2C8 and CYP2C9. Its antimutagenic activity is important for preventing DNA damage.
|
|---|---|
| ln Vitro |
In vitro, Licoisoflavone B exhibits antimutagenic activity against MNU. It inhibits lipid peroxidation with an IC₅₀ of 2.7 μM. It inhibits CYP2C8 and CYP2C9. It also shows anti-inflammatory and antioxidant properties.
|
| ln Vivo |
In vivo, the antimutagenic and antioxidant activities of Licoisoflavone B suggest potential for cancer chemoprevention. Its inhibition of CYP2C8 and CYP2C9 could lead to drug-drug interactions. However, specific in vivo data are limited.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Licoisoflavone B typically involve measuring its inhibition of lipid peroxidation using a model system, such as linoleic acid oxidation, and monitoring the formation of conjugated dienes or malondialdehyde (MDA). Its inhibition of CYP2C8 and CYP2C9 is measured using microsomal preparations and specific substrates.
|
| Cell Assay |
In vitro cell-based assays for Licoisoflavone B use cell lines to study its antimutagenic activity. Cells are treated with the compound and a mutagen (e.g., MNU), and the frequency of mutations is measured. Its anti-inflammatory activity is assessed in LPS-stimulated macrophages by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for Licoisoflavone B would likely employ models of chemical carcinogenesis to study its chemopreventive effects. The compound would be administered to the animals, and the incidence of tumors would be assessed.
|
| ADME/Pharmacokinetics |
Licoisoflavone B has a molecular weight of 352.34 g/mol and a molecular formula of C₂₀H₁₆O₆. It has a purity of ≥95%. It is soluble in organic solvents. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Licoisoflavone B has not been fully characterized. As a natural compound, it is generally considered to have low toxicity. However, its inhibition of CYP2C8 and CYP2C9 suggests potential for drug-drug interactions.
|
| References | |
| Additional Infomation |
Licoisoflavone B has been reported to be found in licorice root, lupin, and other organisms with relevant data. See also: Glycyrrhiza glabra (partial); Glycyrrhiza uralensis root (partial).
Licoisoflavone B is an isoflavone from licorice root with antimutagenic, antioxidant, and anti-inflammatory properties. It inhibits lipid peroxidation and CYP2C8/CYP2C9. Not approved for clinical use. |
| Molecular Formula |
C20H16O6
|
|---|---|
| Molecular Weight |
352.33744
|
| Exact Mass |
352.094
|
| Elemental Analysis |
C, 68.18; H, 4.58; O, 27.24
|
| CAS # |
66056-30-2
|
| PubChem CID |
5481234
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
588.9±50.0 °C at 760 mmHg
|
| Melting Point |
180-183℃
|
| Flash Point |
215.1±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| Source |
Originated from plants: Leguminosae Glycyrrhiza uralensis Fisch.
|
| LogP |
5.52
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C=Cc2c(ccc(c2O)c3coc4cc(cc(c4c3=O)O)O)O1)C
|
| InChi Key |
KIZPADOTOCPASX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O6/c1-20(2)6-5-12-15(26-20)4-3-11(18(12)23)13-9-25-16-8-10(21)7-14(22)17(16)19(13)24/h3-9,21-23H,1-2H3
|
| Chemical Name |
5,7-dihydroxy-3-(5-hydroxy-2,2-dimethylchromen-6-yl)chromen-4-one
|
| Synonyms |
Licoisoflavone B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~141.9 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (3.55 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (3.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8382 mL | 14.1908 mL | 28.3817 mL | |
| 5 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | |
| 10 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
